Meanwhile, the S&P BSE Sensex was up 2.22 points, or 0.01% at 31,275.51. The S&P BSE Small-Cap index was up 99.51 points, 0.65% at 15,410.68.

On the BSE, 1.60 lakh shares were traded on the counter so far as against the average daily volumes of 8.62 lakh shares in the past one quarter. The stock had hit a high of Rs 45.45 and a low of Rs 43.95 so far during the day. The stock had hit a 52-week high of Rs 58.30 on 10 June 2016 and hit a 52-week low of Rs 36.95 on 1 February 2017.

The stock had underperformed the market over the past one month till 2 June 2017, declining 11.64% compared with the Sensex's 4.52% rise. The scrip had also underperformed the market over the past one quarter declining 5.64% as against the Sensex's 8.44% rise. The scrip had also underperformed the market over the past one year advancing 1.69% as against the Sensex's 16.5% rise.

The small-cap company has equity capital of Rs 40.93 crore. Face value per share is Rs 1.

Marksans Pharma had rallied 9.19% in the preceding three trading sessions to settle at Rs 45.15 on Friday, 2 June 2017, from its closing of Rs 41.35 on 30 May 2017.

Marksans Pharma reported consolidated net loss of Rs 3.22 crore in Q4 March 2017, compared with net loss of Rs 5.76 crore in Q4 March 2016. Net sales fell 12.1% to Rs 184.75 crore in Q4 March 2017 over Q4 March 2016.

Marksans Pharma is a global pharmaceutical company. It is engaged in research & development (R&D) and offers CRAMS (contract research and manufacturing services) to global pharmaceutical companies.